Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1

Conditions

Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thymus Neoplasms 1Thymoma 1Ovarian Neoplasms 1Mesothelioma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 9Nivolumab 5tislelizumab 2spartalizumab 2belinostat 2atezolizumab 2Pemetrexed 2Paclitaxel 2Ipilimumab 2Fluorodeoxyglucose F18 2Docetaxel 2Cisplatin 2tocilizumab 1sargramostim 1obinutuzumab 1niraparib 1naptumomab estafenatox 1milademetan 1epacadostat 1enzalutamide 1durvalumab 1cabozantinib 1bosutinib 1Sorafenib 1Sirolimus 1Quality of Life 1Plicamycin 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Immunotherapy, Adoptive 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × bosutinib × Genitourinary × Clear all
NCT03023319 2022-06-14

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

Augusta University

Phase 1 Completed
6 enrolled
GenitourinaryGynecologicOther solid neoplasmThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Mesothelioma, Ovarian Neoplasms, Thymoma, Thymus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡